logo

Mersana Therapeutics, Inc. (MRSN)



Trade MRSN now with
  Date
  Headline
11/7/2022 7:35:49 AM Mersana Therapeutics Q3 Net Loss $59.8 Mln Or $0.61/Shr Vs Loss Of $45.5 Mln Or $0.63/Shr Last Year
8/9/2022 10:11:26 AM Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) FY22 Rev. Estimate To 106.3 M From 2.0 M
8/9/2022 10:10:56 AM Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) FY23 Estimate To -2.04 From -1.75
8/9/2022 10:10:40 AM Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q4 23 Estimate To -0.53 From -0.41
8/9/2022 10:10:28 AM Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q3 23 Estimate To -0.52 From -0.46
8/9/2022 10:10:15 AM Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) Q2 23 Estimate To -0.50 From -0.45
8/9/2022 10:10:00 AM Wedbush Is Cutting Mersana Therapeutics, Inc. (MRSN) Q1 23 Estimate To -0.49 From -0.44
8/9/2022 10:09:42 AM Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) FY22 Estimate To -1.23 From -2.00
8/9/2022 10:09:20 AM Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) Q4 22 Estimate To 0.58 From -0.43
8/9/2022 10:09:01 AM Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) Q3 22 Estimate To 0.43 From -0.51
8/9/2022 10:08:21 AM Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $16 From $14 Price Target
3/21/2022 8:08:40 AM Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $18 Price Target
2/28/2022 4:49:41 PM Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) FY22 Estimate To -1.91 From -2.75
2/28/2022 4:49:06 PM Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) Q4 22 Estimate To -0.53 From -0.67
2/28/2022 4:48:53 PM Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) Q3 22 Estimate To -0.64 From -0.63
2/28/2022 4:48:39 PM Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) Q2 22 Estimate To -0.61 From -0.75
2/28/2022 4:48:15 PM Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) Q1 22 Estimate To -0.11 From -0.71
11/30/2021 9:57:24 AM Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $23 Price Target
11/9/2021 6:13:15 AM Mersana Therapeutics Q3 Net Loss $45.5 Mln Or $0.63/Shr Vs Loss Of $22.5 Mln Or $0.33/Shr Last Year